← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,365	-23	-1%	$173B
2	2 Danaher DHR $158B	2,090	+20	+1%	$144B
3	3 Novartis NVS $279B	1,222	+21	+2%	$15.1B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,177	+13	+1%	$75.1B
5	5 Agilent Technologies A $49.1B	919	-20	-2%	$28.3B
6	6 Illumina ILMN $41B	818	-77	-9%	$19.8B
7	7 Charles River Laboratories CRL $14.4B	621	+10	+2%	$10.1B
8	8 Revvity RVTY $17B	505	-24	-5%	$11.5B
9	9 Alnylam Pharmaceuticals ALNY $30B	453	-23	-5%	$20.9B
10	10 DELISTED CATALENT, INC. CTLT	434	-7	-2%	$9.04B
11	11 CRISPR Therapeutics CRSP $4.86B	405	-12	-3%	$2.5B
12	12 Sarepta Therapeutics SRPT $1.78B	395	-10	-2%	$10.1B
13	13 Ginkgo Bioworks DNA $776M	348	+33	+10%	$2.25B
14	14 Bruker BRKR $8.47B	345	-12	-3%	$6.79B
15	15 Ionis Pharmaceuticals IONS $7.1B	310	+6	+2%	$6.34B
16	16 Azenta AZTA $1.63B	309	+3	+1%	$3.09B
17	17 Guardant Health GH $21.9B	296	-3	-1%	$3.21B
18	18 ARK Genomic Revolution ETF ARKG $2.05B	288	-4	-1%	$433M
19	19 Intellia Therapeutics NTLA $1.6B	285	-5	-2%	$2.53B
20	20 Qiagen QGEN $9.41B	278	-5	-2%	$5.4B
21	21 Pacific Biosciences PACB $619M	273	+2	+0.7%	$2.2B
22	22 10x Genomics TXG $9.52B	256	-17	-6%	$3.75B
23	23 Arrowhead Research ARWR $8.25B	255	-18	-7%	$2.01B
24	24 Veracyte VCYT $3.5B	236	+5	+2%	$1.72B
25	25 Editas Medicine EDIT $349M	221	-16	-7%	$481M